- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01218750
Triple Therapy for Diffuse Diabetic Macular Edema (TTDDME)
Combined Phako-Vitrectomy With ILM Peeling, Retinal Endophotocoagulation, and Intraoperative Use of Bevacizumab for Diffuse Diabetic Macular Edema
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The pathogenesis of the diabetic macular edema is multiple. Therefore treatment of this disease should be combined too. VEGF is involved in pathogenesis of diabetic macular edema and recently anti-VEGF agents such as bevacizumab have been shown to be beneficial in the treatment of this retinal disorder. However, endogenous VEGF is required for visual function. Growing body evidence indicates that VEGF acts also on nonvascular cells, it plays survival role on Muller cells and photoreceptors. Therefore anti-VEGF therapies should be administered with caution and not persistent. Photocoagulation in nonperfused areas eliminate increased production of VEGF, proliferation of RPE and increased production of PEDF in surrounded impact laser area. Vitrectomy with ILM peeling reliefs traction on the macula, improve oxygenation of the macula leading to decreased vascular permeability with subsequent resolution or decrease in DME. Removed ILM contains a part of the Müller cell endfeet and the horizontal gliosis. It is likely that the proliferation of GFAP-stained gliofibrils, observed in microdamaged Müller cells, preserves the blood-retinal barrier, reinforces architectural cohesion, and opposes the installation of the edema. Therefore, we made hypothesis that combined triple therapy was effective for decreasing macular thickness and improvement of vision for eyes with diffuse diabetic macular edema.
It is important for the surgeon to determine the factors that might influence surgical outcome so that patients are chosen for the procedure that they can get benefit from. Therefore, we evaluated the possible preoperative and intraoperative factors that might influence surgical outcomes
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Robaszkiewicz Jacek, dr med.
- Numéro de téléphone: +48604597970
- E-mail: vectra@izet.pl
Sauvegarde des contacts de l'étude
- Nom: Chmielewska Katarzyna, lek.med.
- Numéro de téléphone: +48509142510
- E-mail: kchmielewska@interia.pl
Lieux d'étude
-
-
Szaserów 44
-
Warsaw, Szaserów 44, Pologne, 04-141
- Recrutement
- Military Institute of Medicine
-
Chercheur principal:
- Robaszkiewicz Jacek, dr med.
-
Sous-enquêteur:
- Chmielewska I. Katarzyna, lek. med.
-
Contact:
- Kowal Ewelina
- Numéro de téléphone: (+48) 22 665 707 584
- E-mail: ekowal@wim.mil.pl
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- diagnosis of DDME on clinical exam, definite retinal thickening involving the center of the macula, confirmed by fluorescein angiography, with or without PVD,
- BCVA of 0,3 or worse in log MAR units (<=70 ETDRS letter) and 1,5 or better in log MAR units (>=10 ETRDS letter),
- mean central macular thickness greater than 250 μm on optic coherence tomography (OCT),
- presence of vitreomacular traction or a thickened and taut posterior hyaloid or presence of an epimacular membrane.
Exclusion Criteria:
- significant macular ischemia defined as enlarged perifoveal capillary loss (>1000 µm) by fluorescein angiography,
- the focal macular edema due to focal leakage from microaneurysm,
- ophthalmic disorders associated with macular edema, such as uveitis, branch or central retinal vein occlusion and pseudophakic cystoid macular edema,
- vitreous hemorrhage or tractional retinal detachment secondary to diabetic retinopathy,
- an ocular condition is present such that, visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary abnormalities, dense subfoveal hard exudates),
- history of retinal macular photocoagulation, intravitreal corticosteroids, or other treatment for DME within 3 months prior to enrollment,
- history of any intraocular surgery within prior 6 months.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: edematous tractional epimacular membrane
Diabatic maculopathy comes to the edematous or tractional form.
It is believed that epiretinal membranes are comprised from glial components.
The processes of these cells may invade through the internal limiting membrane of the retina to the vitreous causing the vitreoretinal adhesion and anomalous posterior detachment of vitreous (APVD).
In the macula, APVD causes vitreo-macular traction syndrome, which results in diffuse diabetic macular edema.
If vitreoschisis is present, a place of dissection is crucial.
If break occurs in front of the hyalocytes remaining on the retinal surface, the vitreous layer is thick and easily shrinks concentrically, which results in the formation of epimacular membrane.
|
Three port pars plana vitrectomy is performed by one surgeon (JR).
Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally.
Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps.
Trypan Blue is used to stain the ILM.
Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks.
All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure.
Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Best-corrected visual acuity (BCVA) and central macular thickness (CMT)
Délai: up to 1 week before surgery
|
The best corrected visual acuity (BCVA) for ETDRS chart and central macular thickness (CMT) are assessed preoperatively and during the follow-up period.
OCT is performed 1 mm and 6 mm diameter topography centered at the patient fixation point.
We evaluate mean central retinal thickness and central retinal volume 1 mm and 6 mm in diameter.
|
up to 1 week before surgery
|
Best-corrected visual acuity (BCVA) and central macular thickness (CMT)
Délai: 16 up to 17 weeks after surgery
|
The best corrected visual acuity (BCVA) for ETDRS chart, results are converted to log MAR for statistical analysis.
The central macular thickness (CMT) are assessed 1 mm diameter topography centered at the patient fixation point for OCT-SLO.
We evaluate mean central retinal thickness and central retinal volume 1 mm and 6 mm in diameter.
|
16 up to 17 weeks after surgery
|
Best-corrected visual acuity (BCVA) and central macular thickness (CMT)
Délai: 32 up to 33 weeks after surgery
|
A follow-up examination include: The best corrected visual acuity (BCVA) for ETDRS chart, results are converted to log MAR for statistical analysis.
The central macular thickness (CMT) are assessed 1 mm diameter topography centered at the patient fixation point for OCT-SLO.
We evaluate mean central retinal thickness and central retinal volume 1 mm and 6 mm in diameter.
|
32 up to 33 weeks after surgery
|
Best-corrected visual acuity (BCVA) and central macular thickness (CMT)
Délai: 48 up to 49 weeks after surgery
|
A follow-up examination include: The best corrected visual acuity (BCVA) for ETDRS chart, results are converted to log MAR for statistical analysis.
The central macular thickness (CMT) are assessed 1 mm diameter topography centered at the patient fixation point for OCT-SLO.
We evaluate mean central retinal thickness and central retinal volume 1 mm and 6 mm in diameter.
|
48 up to 49 weeks after surgery
|
Best-corrected visual acuity (BCVA) and central macular thickness (CMT)
Délai: 64 up to 65 weeks after surgery
|
A follow-up examination include: The best corrected visual acuity (BCVA) for ETDRS chart, results are converted to log MAR for statistical analysis.
The central macular thickness (CMT) are assessed 1 mm diameter topography centered at the patient fixation point for OCT-SLO.
We evaluate mean central retinal thickness and central retinal volume 1 mm and 6 mm in diameter.
|
64 up to 65 weeks after surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Presence of vitreomacular traction or epimacular membrane, grade of DR, patients age, HbA1c level, BMI, systemic hypertension
Délai: up to 2 weeks before surgery
|
The demographic characteristics of the patients including: age, grender, metabolic condition: HbA1c level, body mass index, presence of systemic hypertension, ocular condition: diabetic retinopathy stage, previous laser, presence of viteomacular traction or epiretinal membrane are recorded to eveluate the possible association with chance in postoperative BCVA.
|
up to 2 weeks before surgery
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Robaszkiewicz Jacek, dr med., Department of Ophthalmology Military Institute of Medicine
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies oculaires
- Dégénérescence rétinienne
- Maladies rétiniennes
- Dégénérescence maculaire
- Œdème maculaire
- Œdème
- Effets physiologiques des médicaments
- Agents antinéoplasiques
- Agents antinéoplasiques immunologiques
- Inhibiteurs de l'angiogenèse
- Agents modulateurs de l'angiogenèse
- Substances de croissance
- Inhibiteurs de croissance
- Bévacizumab
Autres numéros d'identification d'étude
- 46/WIM/2008
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .